Innovative Arzneimittel

The Innovative Drug theme covers biopharma developers and platforms creating first‑in‑class or best‑in‑class therapies across modalities such as small molecules, biologics, antibody‑drug conjugates, cell and gene therapies, and RNA medicines. Core tracks include target discovery (including computational/AI‑enabled platforms), preclinical and clinical development pipelines, oncology/immunology/rare‑disease franchises, and enabling CRO/CDMO partnerships and regulatory milestones.The sector's total market cap is 1806.51 billion HKD, with a 24h change of -0.33%. Among 40 constituents, 17 are up (42.50%) and 21 are down (52.50%). The top gainer is SIHUAN PHARM (00460), with a 24h increase of +6.81%.Sector dipped on mixed breadth, though leaders outperformed. Stay selective: trade around clinical/policy catalysts; prefer cash‑rich, late‑stage pipelines, adding on weakness as rates and reimbursement signals shape valuations.